ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.64
0.22%
US Tech 100
20,266.40
0.33%
S&P 500
5,969.34
0.35%
US Dollar vs CAD
1.39805
0.00%
Bitcoin
97,625.43
-0.16%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. GlycoMimetics Inc (GLYC)

  7. GlycoMimetics Inc (GLYC) News

GLYC

GlycoMimetics (GLYC)

GlycoMimetics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GLYC
DateTimeSourceHeadlineSymbolCompany
11/12/20247:00AMPR Newswire (US)Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024NASDAQ:GLYCGlycoMimetics Inc
11/07/20243:47PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
11/07/20243:42PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
11/06/20244:41PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
11/06/20246:00AMBusiness WireGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNASDAQ:GLYCGlycoMimetics Inc
11/04/20243:26PMEdgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:GLYCGlycoMimetics Inc
11/04/20241:01PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
10/29/20249:00AMAllPennyStocks.comShares of Biotech Company Up Over 100% Premarket Following Merger & Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
10/29/20249:00AMAllPennyStocks.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementNASDAQ:GLYCGlycoMimetics Inc
10/29/20247:09AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:GLYCGlycoMimetics Inc
10/29/20247:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
10/29/20246:00AMBusiness WireGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaNASDAQ:GLYCGlycoMimetics Inc
10/29/20245:30AMBusiness WireGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointNASDAQ:GLYCGlycoMimetics Inc
08/15/20244:01PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
08/14/20243:13PMEdgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:GLYCGlycoMimetics Inc
08/08/20243:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
07/30/20242:55PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
07/29/20246:24PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:GLYCGlycoMimetics Inc
07/25/20248:00AMBusiness WireGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanNASDAQ:GLYCGlycoMimetics Inc
06/13/20243:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/04/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
06/04/20246:00AMBusiness WireGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
05/29/20243:01PMBusiness WireGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024NASDAQ:GLYCGlycoMimetics Inc
05/09/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLYCGlycoMimetics Inc
05/06/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
05/06/20245:00AMBusiness WireGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)NASDAQ:GLYCGlycoMimetics Inc
04/25/20246:00AMBusiness WireGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:GLYCGlycoMimetics Inc
03/27/20246:00AMBusiness WireGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023NASDAQ:GLYCGlycoMimetics Inc
03/13/20246:00AMBusiness WireGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024NASDAQ:GLYCGlycoMimetics Inc
03/01/20248:16AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLYCGlycoMimetics Inc
 Showing the most relevant articles for your search:NASDAQ:GLYC

Your Recent History

AQSE
PEG.GB
Petards
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved